Ongoing study in MCI and AD patients. Measurement at 24 months:  Assess safety and tolerability. Changes in memory function (memory tested on Ray Auditory Verbal Learning Task and Benson Complex Figure Draw and Memory). Changes in brain imaging and biomarkers (amyloid, tau, neurofilament). The gene discussed is MAPT; the disease is Alzheimer disease.